Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin
Open Access
- 1 December 2006
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 149 (7) , 920-930
Abstract
The anticancer drugs doxorubicin and bleomycin are well-known for their oxidative stress-mediated side effects in heart and lung, respectively. It is frequently suggested that iron is involved in doxorubicin and bleomycin toxicity. We set out to elucidate whether iron chelation prevents the oxidative stress-mediated toxicity of doxorubicin and bleomycin and whether it affects their antiproliferative/proapoptotic effects. Cell culture experiments were performed in A549 cells. Formation of hydroxyl radicals was measured in vitro by electron paramagnetic resonance (EPR). We investigated interactions between five iron chelators and the oxidative stress-inducing agents (doxorubicin, bleomycin and H(2)O(2)) by quantifying oxidative stress and cellular damage as TBARS formation, glutathione (GSH) consumption and lactic dehydrogenase (LDH) leakage. The antitumour/proapoptotic effects of doxorubicin and bleomycin were assessed by cell proliferation and caspase-3 activity assay. All the tested chelators, except for monohydroxyethylrutoside (monoHER), prevented hydroxyl radical formation induced by H(2)O(2)/Fe(2+) in EPR studies. However, only salicylaldehyde isonicotinoyl hydrazone and deferoxamine protected intact A549 cells against H(2)O(2)/Fe(2+). Conversely, the chelators that decreased doxorubicin and bleomycin-induced oxidative stress and cellular damage (dexrazoxane, monoHER) were not able to protect against H(2)O(2)/Fe(2+). We have shown that the ability to chelate iron as such is not the sole determinant of a compound protecting against doxorubicin or bleomycin-induced cytotoxicity. Our data challenge the putative role of iron and hydroxyl radicals in the oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin and have implications for the development of new compounds to protects against this toxicity.Keywords
This publication has 64 references indexed in Scilit:
- The role of reactive oxygen and nitrogen species in cellular iron metabolismFree Radical Research, 2006
- Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbitsPharmacological Research, 2005
- DexrazoxaneDrugs, 2005
- Intracellular Labile Iron Modulates Adhesion of Human Monocytes to Human Endothelial CellsArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPharmacological Reviews, 2004
- A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicinBiochemical Pharmacology, 1999
- Doxorubicin-induced Apoptosis in Spontaneously Hypertensive Rats: Differential Effects in Heart, Kidney and Intestine, and Inhibition by ICRF-187Journal of Molecular and Cellular Cardiology, 1996
- Bleomycin: Revival of an old drugGeneral Pharmacology: The Vascular System, 1996
- The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexesInflammation Research, 1993
- Mobilization of iron from reticulocytesFEBS Letters, 1979